Last reviewed · How we verify

General Anesthesia (GA)

The University of Texas Health Science Center, Houston · FDA-approved active Small molecule

General anesthesia depresses the central nervous system through multiple molecular pathways to produce unconsciousness, analgesia, and muscle relaxation.

General anesthesia depresses the central nervous system through multiple molecular pathways to produce unconsciousness, analgesia, and muscle relaxation. Used for Induction and maintenance of general anesthesia for surgical procedures, Sedation in intensive care settings.

At a glance

Generic nameGeneral Anesthesia (GA)
SponsorThe University of Texas Health Science Center, Houston
Drug classGeneral anesthetic (combination therapy)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

General anesthesia typically involves a combination of agents (intravenous induction agents, inhaled volatile anesthetics, opioids, and neuromuscular blockers) that work synergistically. These agents enhance inhibitory GABAergic neurotransmission, inhibit excitatory glutamatergic signaling, and modulate other ion channels and receptors in the CNS to produce loss of consciousness and suppression of protective airway reflexes. The exact molecular mechanisms remain incompletely understood but involve multiple targets including GABA-A receptors, NMDA receptors, and potassium channels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: